KAWASAKI, Japan, Dec 11, 2024 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited today announced that it will transfer 100% of its shares in Fujitsu Communication Services Limited to Persol Business Process Design Co., Ltd. The two companies have concluded an agreement to this end and aim to conduct the share transfer on February 3, 2025.1. Background and purpose of the share transferFujitsu is working towards expanding its service solutions as per its business model and portfolio strategy, which was set as a key initiative of the medium-term management plan announced in May 2023.Fujitsu Communication Services has contributed to the realization of a safe and secure system environment for its customers through maintenance and operation support, including via contact centers and service desks in Japan. The company’s strength lies in its expertise in developing human resources that can realize a stable support system and that have wide ranging IT skills developed through product support and it continues to promote customer digital transformation (DX).Persol Business Process Design is part of the Persol Group which develops comprehensive human resource services. Its aim is to "realize a society that is abundant with healthy workplaces" through providing services related to business process outsourcing (BPO), contact centers, sales marketing, and business process consulting. By upgrading and optimizing processes, the company aims to enhance its services and corporate value to create lasting effects.The two companies reached this agreement based on the judgment that the share transfer would allow for further expansion of business areas by combining the strengths of both companies, and improvement of productivity and engagement achieved through economies of scale and BPO DX/CX.Fujitsu will continue to meet the needs of its customers by providing services for Fujitsu Communication Services-run contact centers, service desks, etc.2. Overview of CompaniesCompany NameFujitsu Communication Services Limited(A wholly-owned subsidiary of Fujitsu Limited)HQ LocationYOKOHAMA i-MARK PLACE 4-4-5 Minatomirai, Nishi-ku, Yokohama-shi, Kanagawa Prefecture, JapanPresident and Representative DirectorMikiwa KanaiCapital100 million yenDate Est.December 1994No. Employees4,400 (as of March 2024)Business OverviewContact center and IT support outsourcing servicesNet sales23.9 billion yen (FY ended March 2024) Company NamePersol Business Process Design Co., Ltd.(Persol Holdings Co.,Ltd.)HQ LocationGranpark Tower 33 F 3-4-1 Shibaura, Minato-ku, TokyoPresident and Representative DirectorKazuyuki IchimuraCapital310 million yenDate Est.September 1977No. Employees18,253 (as of July 1, 2024) *Number of employees in all types of employmentBusiness OverviewBPO, help desk contact center, sales marketing,business process consulting, HR solutions, healthcare solutions, productsNet sales57.6 billion yen (ended March 2024)About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2024 JCN Newswire via SeaPRwire.com.
Eisai’s “URECE(R)” (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
TOKYO, Dec 11, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. announced today that it has received approval for “URECE®” (brand name in China: “优乐思®”, generic name: dotinurad) from the National Medical Products Administration in China as a treatment for gout patients with hyperuricemia.This approval is based on the results of a multicenter, active-controlled, double-blind, parallel-group, randomized, Phase 3 study conducted by Eisai in China.1 In this study, 451 gout patients were randomized into either the dotinurad group or febuxostat group in a 1:1 ratio. The results of this study showed that the proportion of subjects with serum uric acid levels of 6.0 mg/dL or less at 24 weeks, which was the primary endpoint, was 73.6% [95% confidence interval (CI): 67.8, 79.5] in the dotinurad group and 38.1% [95% CI: 31.6, 44.5] in the febuxostat group, confirming the statistical superiority of dotinurad 4 mg over febuxostat 40 mg (difference of proportion 35.87% [95% CI: 27.36, 44.37, p<0.001]).The most common adverse events were gouty arthritis, COVID-19, and liver function abnormality in the dotinurad group, and gouty arthritis, COVID-19, and increased alanine aminotransferase (ALT) in the febuxostat group. No new safety concerns with dotinurad were observed.“URECE” is a new therapeutic medicine for gout and hyperuricemia discovered by FUJI YAKUHIN. It suppresses uric acid reabsorption and lowers blood uric acid levels by selectively inhibiting the urate transporter (URAT1) related to reabsorption of uric acid in the kidney. Eisai concluded a license agreement with FUJI YAKUHIN for China and five ASEAN member states: Indonesia, Malaysia, Myanmar, the Philippines, and Thailand, granting exclusive development and distribution rights in these countries. URECE was approved in Thailand for gout and hyperuicemia in September, 2024. In Japan, FUJI YAKUHIN obtained manufacturing and marketing approval for URECE in January 2020 and launched it in May 2020.It is estimated that there are currently about 16 million patients with gout in China.2 It is expected that the number of patients will further increase in the near future due to changes in lifestyle and dietary preferences in accordance with socioeconomic development.Eisai is committed to providing “URECE” to more patients with gout in China, including through its inclusion in the National Reimbursement Drug List (NRDL), and will contribute to improving the quality of life (QOL) of patients.“优乐思®” Product OutlineChinese Trade name: “优乐思” (URECE)Chinese generic name: 多替诺雷片 (Dotinurad Tablets)Indication for use: It is indicated for gout patients with hyperuricemia.Dosage and administration: For oral use, the usual adult initial dosage is 1 mg of dotinurad once daily. The dose level should then be gradually increased as needed by checking blood uric acid levels. The usual maintenance dosage is 2 mg once daily and may be adjusted according to the patient’s condition, but up to 4 mg once daily.About “URECE®” (Dotinurad)URECE is a therapeutic medicine for gout and hyperuricemia discovered by FUJI YAKUHIN. URECE selectively inhibits URAT1, one of the uric acid transporters, thus preventing reabsorption of uric acid by the kidneys and promoting uric acid excretion in the urine. In addition, URECE has a small effect on other transporters affecting uric acid secretion, so it reduces serum uric acid levels at lower doses. URECE is expected to have a low risk of side effects and drug interactions.In Japan, FUJI YAKUHIN obtained manufacturing and marketing approval for URECE in January 2020 and launched it in May 2020.About the Phase 3 Clinical Trial (Study FYU-981-J086-301)1This was a multicenter, active-controlled, double-blind, parallel-group, randomized, Phase 3 study conducted to confirm the superiority of dotinurad 4mg over febuxostat 40mg as the primary evaluation, assess safety, and confirm the non- inferiority of dotinurad 2mg to febuxostat 40mg as the secondary evaluation in Chinese patients with gout.Patients with gout and serum uric acid (SUA) levels exceeding 7.0 mg/dL were randomly assigned to either the dotinurad group or the febuxostat group in a 1:1 ratio, investigational product treatment for 24 weeks (the dotinurad group received 1mg/day for 4 weeks, 2mg/day for 8 weeks, and 4mg/day for 12 weeks, while the febuxostat group received 20mg/day for 4 weeks and 40mg/day for 20 weeks). The primary endpoint was the proportion of patients with SUA ≤6.0mg/dL at 24 weeks, and the secondary endpoint was the proportion of patients with SUA ≤6.0mg/dL at 12 weeks.Of the total 451 patients, 225 were assigned to the dotinurad group and 226 to the febuxostat group. Of these, 441 patients (220 in the dotinurad group and 221 in the febuxostat group) were included in the Full Analysis Set (FAS).For the primary endpoint, the proportion of patients with SUA ≤6.0mg/dL at 24 weeks was 73.6% [95% confidence interval (CI): 67.8, 79.5] in the dotinurad group and 38.1% [95% CI: 31.6, 44.5] in the febuxostat group, confirming the statistical superiority of dotinurad 4mg over febuxostat 40mg (difference of proportion 35.87% [95% CI: 27.36, 44.37, p<0.001]).For the secondary endpoint, the proportion of patients with SUA ≤6.0mg/dL at 12 weeks was 55.5% in the dotinurad group and 50.5% in the febuxostat group, confirming the statistical non-inferiority of dotinurad 2mg to febuxostat 40mg (difference of proportion 5.24% [95% CI: -3.69, 14.17]).The most common adverse events were gouty arthritis, COVID-19, and liver function abnormality in the dotinurad group, and gouty arthritis, COVID-19, and increased alanine aminotransferase (ALT) in the febuxostat group. No new safety concerns with dotinurad were observed.(1) Sun J, Wang Y, Zhang X, et al. POS0255 A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY COMPARING EFFICACY OF DOTINURAD AND FEBUXOSTAT FOR THE TREATMENT OF GOUT IN CHINESE SUBJECTS. Annals of the Rheumatic Diseases 2024;83:407-408.(2) For the estimated data regarding the number of patients with gout: Data of morbidity prevalence rate - Rui Liu et al., Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis, BioMed Research International, Volume 2015, Article ID 762820Estimated data calculated from United Nations World Population Estimates - World Population Prospects, URL:https://population.un.org/wpp/ Media Inquiries:Eisai Co., Ltd.Public Relations Department TEL: +81-(0)3-3817-5120 Copyright 2024 JCN Newswire via SeaPRwire.com.
關於安潔莉娜·裘莉在 Netflix 電影瑪麗亞中飾演的真實歌劇女高音瑪麗亞·卡拉斯,你必須知道的事
(SeaPRwire) -本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。觀看 Netflix 由 Angelina Jolie 主演的電影《Maria》前,你應該了解歌劇演唱家 Maria Callas 的一些事
特朗普將取代莉娜·汗出任聯邦貿易委員會主席,並任命金伯利·吉爾福伊爾為希臘大使
(SeaPRwire) - 當選總統唐納德·特朗普星期二又做出了一系列人事任命,選擇安德魯·弗格森為下一任聯邦貿易委員會主席,金伯利·吉爾福伊爾為駐希臘大使,湯姆·巴拉克為駐土耳其大使。 弗格森,現任聯邦貿易委員會五名委員之一,將接替Lina Khan,Khan因阻止數十億美元的企業收購案,並以反競爭行為為由起訴亞馬遜和Meta而成為華爾街和矽谷的眼中釘。 「安德魯在捍衛大科技公司言論審查,以及保護我們偉大國家的言論自由方面,有著良好的記錄,」特朗普在Truth Social上寫道,並補充說:「安德魯將成為我們國家歷史上最美國優先、最支持創新的聯邦貿易委員會主席。」 巴拉克是一位富有的金融家,他在20世紀80年代幫助特朗普協商購買著名的Plaza Hotel時結識了特朗普。他被指控利用與前總統的私人關係秘密推動阿聯酋的利益,但在2022年的一場聯邦審判中被判無罪。 特朗普稱他為「一位備受尊敬且經驗豐富的理性之聲」。 吉爾福伊爾是前加州檢察官和電視新聞人物,她領導了特朗普2020年競選活動的籌款工作,並在2020年與小唐納德·特朗普訂婚。特朗普稱她為「一位親密的朋友和盟友」,並讚揚她的「敏銳的智慧使她非常合格」。選舉之夜,吉爾福伊爾與特朗普家族一起在台上。 「我為金伯利感到非常驕傲。她熱愛美國,她一直想以大使的身份為國家服務。她將成為美國優先的傑出領導者,」小唐納德·特朗普發文道。 大使職位必須得到美國參議院的批准。 吉爾福伊爾在社交媒體上發文表示,她「榮幸地接受特朗普總統的提名,擔任下一任駐希臘大使,我期待獲得美國參議院的支持」。 特朗普星期二還宣布,他已選定雅各布·赫爾伯格為下一任主管經濟增長、能源和環境的國務院次長,丹·主教為預算管理辦公室的預算副主任。 在聯邦貿易委員會更換Khan很可能意味著,該委員會在反托拉斯執法方面將採取更寬鬆的措施。新任主席預計將任命聯邦貿易委員會反托拉斯和消費者保護部門的新主任。 「這些變化可能會使聯邦貿易委員會比近年來更偏向企業,儘管其程度還有待觀察,」Holland & Knight消費者保護律師Anthony DiResta在最近的一份分析中寫道。 拜登政府阻止的交易可能會在特朗普執政下重獲新生。 例如,新領導層可能會更願意接受美國兩家最大的超市連鎖店Kroger和Albertsons提出的合併計劃,兩家公司在2022年達成了一項價值246億美元的合併協議。兩名法官在星期二晚上叫停了這項合併。 聯邦貿易委員會今年早些時候在聯邦法院提起訴訟,阻止這項合併,聲稱這項交易將消除競爭,導致物價上漲和工人工資下降。這兩家公司表示,合併將幫助他們降低價格,並與沃爾瑪等更大的競爭對手競爭。 其中一名法官表示,聯邦貿易委員會已經證明它很可能在行政聽證會上勝訴。 然而,鑑於公眾對高昂食品價格的廣泛關注,特朗普政府可能不會完全放棄聯邦貿易委員會阻止這項交易的努力,一些專家表示。 而且,聯邦貿易委員會可能會繼續審查大型科技公司是否存在任何反競爭行為。許多共和黨政客指控Meta等公司審查保守派觀點,而特朗普陣營的一些官員,最著名的是當選副總統JD Vance,此前曾表示支持Khan對大型科技公司的審查。 —Rugaber從華盛頓報道。美聯社記者Jill Colvin在紐約和Colleen Long在華盛頓對此報道有貢獻。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。 ```
觀看馬里布肆虐的富蘭克林大火照片
(SeaPRwire) - 截至週二下午,加州一場被稱為富蘭克林大火的野火已蔓延至加州太平洋沿岸超過 2,500 英畝,包括馬里布,導致疏散並出動 800 多名消防員前往現場。 根據洛杉磯縣消防局和加州林業和消防保護局 (Cal Fire) 的說法,大火於週一晚上 11 點左右在南馬里布峽谷路附近開始燃燒,截至週二,火勢零% 受控。大火起因尚未公布。官員表示,火焰非常猛烈,正在改變當地天氣,根據國家氣象局的說法,「將」40 英里/小時的風「彎曲」到「火中」。週一晚上,該地區約有 40,000 名用戶斷電,希望能控制對電氣設備的任何損壞,以免引發更多火災。位於馬里布的佩珀代因大學週二停課,週一晚上發布的原地避險令於週二上午解除。 洛杉磯縣警長羅伯特·盧納週二在新聞發布會上表示,已在馬里布峽谷路以東和皮烏馬路以南發布疏散令及警告,共有 18,000 人以及 8,100 個住宅和企業受到影響。洛杉磯縣消防局局長安東尼·馬龍也於週二表示,少量房屋已被「摧毀」,該部門希望在下午之前達成一定程度的控制。 「消防官員和急救人員正在不懈努力地保護生命和財產。我敦促受影響地區的所有居民保持警惕並遵守疏散令。」加州州長加文·紐森週二表示。 圖片顯示消防員正在與猛烈的火焰搏鬥,汽車燃燒,濃煙滾滾。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。 ```
為何住房是對抗氣候變遷的第一道防線
(SeaPRwire) - 氣候變化正在重塑世界,加劇全球在健康、就業、教育和個人安全方面的挑戰。然而,世界領導人往往忽視了氣候危機最直接影響人們的地方:他們的住所。 越來越嚴重的自然災害、海平面上升和極端天氣事件,不僅威脅著現有的房屋,也推高了建造和維護安全、體面住房的成本。Habitat for Humanity 通過我們在 70 多個國家的工作,親眼目睹了低收入家庭——儘管他們對全球碳排放的貢獻最少——卻往往承受著氣候變化的最大衝擊。這一點對於居住在貧民窟和其他非正式定居點的超過十億人來說尤其如此。 但好消息是:如果我們願意真正傾聽,了解氣候變化如何影響他們的日常生活,並投資於大規模努力,讓更多房屋安全、健康和具有韌性,這些相同的社區就掌握著解決方案。 利害關係高到不能再高。到 2050 年,氣候遷徙可能導致全球約有 人口流離失所,低收入和快速城市化的國家將受到最大影響。與大多數受氣候影響的社區將遷移到高收入國家的擔憂相反,大多數人仍然留在本國境內,許多人居住在非正式定居點的簡陋房屋中。這些地區已經容易受到氣候影響,隨著流離失所者的湧入,將承受更大的壓力,給有限的資源帶來巨大壓力。 無論我們是否意識到,我們稱之為家的地方是氣候危機的核心——既是造成問題的原因,又具有減輕氣候變化影響的巨大潛力。根據聯合國環境規劃署的數據,建築環境佔全球溫室氣體排放量的 21%,其中住宅建築佔總排放量的 17%。隨著地球變暖和氣候災害加劇,住房的作用變得更加關鍵——不僅在於減少排放,還在於為受影響最嚴重的人們提供穩定和安全。 世界領導人有機會——我認為也有義務——關注氣候遷徙,尤其是在全球南方。對此視而不見,就等於忽略了解決氣候挑戰以及經濟發展、健康和教育等關鍵問題中的一塊重要拼圖。 住房促進氣候韌性和發展 許多研究證明,擁有一個安全可靠的家園會提高許多可衡量成果的生活質量。即使是最簡單的住所也能極大地影響居住者生活軌跡。然而,對於居住在非正式定居點的數百萬家庭來說,房屋往往缺乏基本服務、土地所有權保障和氣候韌性。這些挑戰令人望而生畏,但也為應對氣候變化提供了獨特的機會。通過投資為非正式定居點居民提供充足的住所,我們不僅將解決一個道德責任,還將釋放出一種最聰明、最有效的戰略,以構建一個可持續和公平的未來。 代表 Habitat for Humanity 進行的研究表明,充足的住房是福祉和可持續性的強大催化劑。它會影響非正式定居點居民和更廣泛社會的國家經濟發展、收入、健康和教育。如果大規模升級非正式定居點的住房,一些國家的GDP和人均收入將增長多達10.5%,並且可能有多達4160萬額外兒童可以入學。 儘管住房與氣候變化之間的聯繫很明顯,但世界領導人仍然忽視獲得充足住所作為一種適應和減緩工具。 氣候行動計劃中的嚴重差距 國家自主貢獻(NDC)是全球氣候行動的基石,闡述了每個國家根據《巴黎協定》減少碳排放和適應氣候變化影響的承諾。然而,所有國家中,只有 在他們的 NDC 中對住房部門表示高度重視,而略多於 則完全沒有優先考慮住房。 這種遺漏是一個明顯的疏忽。以住房為中心的措施,使社區和家庭適應氣候影響,包括全面的貧民窟改造,對於氣候行動和推進可持續發展目標至關重要。這些戰略不僅應對氣候韌性,還為改善健康、教育和經濟成果提供途徑。 為應對這些挑戰,Habitat for Humanity 已經調整了我們的工作方式。在世界各地,Habitat 建造和翻新房屋,增加可持續利用自然資源和施工方法的比例,同時減少房屋整個生命週期中的溫室氣體排放。 為了擴大這些努力,我們敦促七國集團領導人在其氣候行動中認識並支持住房減緩和適應措施,尤其是非正式定居點的住房減緩和適應措施。通過投資住房解決方案,各國可以在實現其氣候目標的同時,促進更具韌性、可持續和公平的社區。 家不僅僅是居住的地方。家意味著更好的健康、安全和保障,是家庭和地球更美好未來的基礎。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
地球四分之三地區永久乾涸 “`
(SeaPRwire) - 在我們太陽系的家園中,只有地球表面充滿了液態水。大約 71% 的地球表面覆蓋著海洋、湖泊、河流和溪流,為超過三十億年的全球生命提供了生命之源。但地球的部分地區不像以前那樣濕潤了,這主要歸咎於那些生命形式中最高級的——我們。 根據聯合國防治荒漠化公約 (UNCCD) 的一份報告,人類造成的氣候變化正導致地球 77.6% 的陸地面積處於永久性乾燥狀態,這種持續的乾旱在 1990 年至 2020 年的 30 年間一直在發生。在這三十年裡,全球乾旱地區擴大了 430 萬平方公里(166 萬平方英里),面積幾乎是印度國土的三分之一。而當 UNCCD 說乾旱時,他們指的是永久性的乾旱。 「與乾旱——暫時的降雨量低——不同,乾旱代表著一種永久的、持續的轉變,」UNCCD 執行秘書易卜拉欣·蒂亞夫 (Ibrahim Thiaw) 在報告發布時發表聲明說——該報告是在各國齊聚沙烏地阿拉伯參加……時發布的。「乾旱會結束。然而,當一個地區的氣候變得乾燥時,恢復到以前狀況的能力就會喪失。目前影響全球廣大土地的乾燥氣候將不會恢復到以前那樣,這正在重新定義地球上的生命。」 的確如此。根據 UNCCD 的數據,在研究的三十年間發生的這種轉變正在導致 GDP 損失、被迫遷徙、因沙塵暴造成的死亡人數增加、野火加劇、土地侵蝕、植被退化、水和土壤鹽鹼化等等。 「如果不採取協同努力,數十億人將面臨飢餓、流離失所和經濟衰退的未來,」UNCCD 科學政策接口主席妮可·巴格爾 (Nicole Barger) 在一份聲明中說。「然而,通過採用創新解決方案和促進全球團結,人類可以應對這一挑戰。問題不在於我們是否有工具來應對——而在於我們是否有意願採取行動。」 就本報告而言,乾旱是根據三個變量測量的:環境降雨量、蒸騰作用——或通過植物將水分轉移到大氣中的速率——以及蒸發。乾旱地區被定義為年潛在蒸發量和蒸騰量比平均降水量高 45% 的地區。目前,滿足該定義的地區佔地球上所有土地(不包括南極洲)的 40.6%。預計到本世紀末,全球目前潮濕地區的另外 3% 將變成乾旱地區。 歐洲尤其強烈地感受到了目前的燃燒,該大陸高達 95.9% 的地區都經歷了乾旱。同樣受到重創的還有巴西、美國部分地區、地中海地區、非洲中部和東亞。當然,水既不會被創造也不會被消滅,只是被重新分配。隨著地球 77.6% 的地區變得更加乾燥,22.4% 的地區變得更加濕潤,尤其是在美國中部、安哥拉的大西洋沿岸和東南亞——這些地區目睹了越來越強大的風暴和洪水。但乾旱是全球的主導趨勢,它代價高昂。 到本世紀末,地球上高達 20% 的土地可能會經歷生態系統的突然轉變,例如森林變成草原,伴隨著生態系統的滅絕和崩潰。農業也可能受到影響。在非洲,乾旱導致 GDP 下降了 12%,部分原因是耕地退化。按照目前的乾旱速度,預計到本世紀中葉,撒哈拉以南非洲目前的作物產量將減少 17% 到 22%。到 2040 年,每年將損失 2000 萬噸玉米產量,以及 1900 萬噸稻米、800 萬噸大豆和 2100 萬噸小麥。 超過 23 億人生活在乾旱加劇的影響範圍內,他們的健康可能會受到環境變化的影響。根據 UNCCD 的分析,預計糧食儲備減少將導致撒哈拉以南非洲兒童發育遲緩增加 55%。目前,超過 6.2 億人——佔該大陸人口的一半——生活在乾旱地區。由於乾旱,非洲和中東地區的水資源減少了 75%——不僅導致飲用水短缺,而且還導致衛生所需的資源短缺。 在美國沙漠西南部,專家預計到本世紀末,粗粒大氣塵埃將增加 57%,更危險的細粒大氣塵埃將增加 38%。這反過來可能導致因肺部疾病造成的過早死亡增加 220%,以及住院人數增加 160%。 就其本質而言,目前乾旱的永久性掩蓋了簡單的解決方法;從長遠來看,減少溫室氣體排放將有助於降低全球氣溫,但乾旱化造成的變化——例如乾旱草原的蔓延以及由於野火造成的森林損失——將不會在數百年內,甚至根本無法逆轉。目前,人類所能做的最好的事情就是適應。UNCCD 建議回收廢水和經濟滴灌作為節省和節約稀缺水資源的方法。……倡議——由非洲聯盟於 2007 年啟動——旨在到 2030 年用低需水綠化植物重新種植 2.5 億英畝目前退化的土地,封存 2.5 億噸碳,創造 1000 萬個新的綠色就業機會。 其他補救措施包括……等倡議,該倡議同樣正在使中國大片地區重新綠化,防止沙塵暴和水分蒸發損失。獨立和工業化農場也需要以其他方式適應,改種耐旱作物,如高粱、秋葵和蠶豆——同時注意輪作這些作物以及其他各種類似作物,以避免建立易受疾病影響的農業單一栽培模式。牲畜數量也必須改變,例如,耐熱性比奶牛更強的山羊可以替代奶牛生產牛奶。在沙烏地阿拉伯等工業化國家,海水淡化是彌補乾旱加劇的另一種強有力方法。 這些措施都不是完美的解決方案;所有這些措施以及更多措施將是必要的,以清理人類在整個工業時代造成的環境混亂。「隨著世界大片土地變得更加乾旱,不採取行動的後果將越來越嚴重,」UNCCD 首席科學家巴倫·奧爾 (Barron Orr) 在一份聲明中說。「適應不再是可選的——而是必須的。」本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。 ```
BOM Network Unveils Solutions to Tokenize Real-World Assets
Hong Kong – December 11, 2024 – (SeaPRwire) – Recently, BOM Network is proud to unveil its solutions to tokenize a wide range of real-world assets, from real estate to commodities, and use these tokens for trading, lending, or as collateral. Real-World Assets (RWA): The Bridge Between Traditional Finance and Blockchain Revolution In recent years, the crypto market has undergone remarkable growth, but its volatility and limited real-world use cases have often raised concerns. Real-World Assets (RWA) are emerging as a pivotal trend that may fundamentally reshape the blockchain and crypto space by creating a more stable and tangible connection to traditional finance. The tokenization of RWAs allows for real estate, commodities, and other physical assets to be represented on the blockchain, unlocking liquidity and expanding investment opportunities.RWAs bridge the gap between traditional assets and decentralized finance (DeFi), bringing stability, security, and trust into the often volatile crypto markets. This fusion offers several key benefits: Access to Illiquid Assets Increased Liquidity and Market Efficiency Global Access The Future of Banking and RWA Integration BOM Network is one standout project in the RWA space, focusing on integrating blockchain with traditional financial services. BOM Network’s unique approach lies in its emphasis on combining traditional banking services with the efficiency of blockchain, making it an attractive solution for institutions looking to bridge the gap between old and new financial systems. BOM Network has already established partnerships with global financial institutions, offering a scalable and secure way for investors to participate in the RWA market. Its platform is designed for both retail and institutional investors, making it a key player in the future of decentralized finance. By integrating RWAs into its ecosystem, BOM Network aims to drive the mainstream adoption of blockchain technology and create a more efficient, liquid, and globally accessible financial system. As the tokenization of RWAs gains traction, projects like BOM Network are leading the charge toward a more stable, diversified, and globally inclusive crypto market. About BOM Network BOM is the perfect bridge for capital from the real world to the Blockchain world. Meet a huge supply and demand of borrowing and lending from the real world into the cryptocurrency market. RWAs are likely to accelerate institutional adoption of blockchain technology. Moreover, the introduction of RWAs will catalyze regulatory development as governments and financial authorities adapt to this new intersection of traditional assets and blockchain technology. This convergence will bring crypto further into the mainstream, providing a fertile ground for innovation and growth. Social Links X: https://x.com/BOM_Network Telegram: https://t.me/BOMNetworkCommunity YouTube: https://www.youtube.com/@bom_network Media Contact Brand: BOM Network Contact: Media contact Email: support@bomnetwork.io Website: https://bomnetwork.io The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
BDO announces winners of the 6th BDO ESG Awards 2024
HONG KONG, Dec 11, 2024 - (ACN Newswire via SeaPRwire.com) - BDO, the world’s fifth largest accountancy and advisory network, has announced the winners of the 6th BDO ESG Awards (the Awards). The winning companies have integrated ESG principles and climate change considerations into their business strategies. They have actively emphasised the importance of ESG and promoted its development by implementing influential and long-term sustainable development measures. This year, the Awards received strong support from listed companies, with more than 110 companies participating at the nomination stage, a six-year high. All finalists were invited to attend the awards ceremony to witness the winners honoured. (Click here or view the full list below*)Once again, “Carbon Neutrality” has been selected to be this year’s theme, emphasising the important role that companies play in mitigating climate change and shaping a green future. The Theme Awards are dedicated to recognising listed companies that have demonstrated best practices in “Carbon Neutrality”, including reducing carbon emissions and planning and adopting relevant measures. The companies competing for this year’s Theme Awards were outstanding and evenly matched. A total of three companies won this award, setting a new record.Mr Andrew Lam, Managing Director, BDO, said, “The BDO ESG Awards first launched in 2018 when listed companies began to explore the implementation of ESG initiatives. Today, we are pleased to see that an increasing number of listed companies are recognising the importance of ESG and pursuing long-term ESG development. The Awards have now gained considerable market recognition, and as an advocate of sustainable development, BDO is delighted to see an increasing number of Hong Kong-listed companies paying attention to ESG. Through the judging process, we have observed that the quality of the ESG initiatives implemented by the participating companies has improved and become more forward-looking. As the importance and influence of ESG continues to grow, we hope to work with all kinds of industries through the Awards to improve Hong Kong's green standards and consolidate the city’s position as a green financial centre.”Mr Johnson Kong, Managing Director, BDO, said, “In light of growing social awareness of sustainability and social responsibility, more and more investors and organisations are incorporating ESG factors into their investment decisions and tend to support companies that meet ESG standards. By implementing ESG policies, companies can build a good reputation that will enhance their competitiveness and attract more investors. As a professional in this field, BDO is committed to supporting Hong Kong-listed companies in various areas, such as assisting them in ESG reporting and risk management, and providing them with recommendations to improve ESG performance. We hope the Awards will raise ESG awareness among all stakeholders in society so that more listed and unlisted companies in Hong Kong will prioritise the importance of ESG practices in the future.”Mr Ricky Cheng, Director and Head of Risk Advisory, BDO, said, “This year’s winners come from a variety of industries, and all of the nominated companies have demonstrated outstanding performance in various areas of competition. BDO is proud of the winning companies dedicated to sustainable development, and we are thrilled to support all those who are making strides toward a more environmentally friendly and responsible business landscape through this award and our expertise.”BDO ESG Awards 2024 Winners (listed in alphabetical order) Best in ESG – Large Market CapitalisationBOC Hong Kong (Holdings) Limited (02388.HK)HKT Trust and HKT Limited (06823.HK)Lenovo Group Limited (00992.HK)Best in ESG – Middle Market CapitalisationAAC Technologies Holdings Inc. (02018.HK)Kerry Properties Limited (00683.HK)Xinyi Solar Holdings Limited (00968.HK)Best in ESG – Small Market CapitalisationConcord New Energy Group Limited (00182.HK)Shun Tak Holdings Limited (00242.HK)Yuexiu Services Group Limited (06626.HK)Best in Reporting – Large Market CapitalisationHKT Trust and HKT Limited (06823.HK)Sino Biopharmaceutical Limited (01177.HK)Techtronic Industries Company Limited (00669.HK)Best in Reporting – Middle Market CapitalisationKerry Properties Limited (00683.HK)PCCW Limited (00008.HK)Xinyi Solar Holdings Limited (00968.HK)Best in Reporting – Small Market CapitalisationNew World Department Store China Limited (00825.HK)Xinyi Energy Holdings Limited (03868.HK)Yuexiu Services Group Limited (06626.HK)ESG Report of the Year – Large Market CapitalisationHKT Trust and HKT Limited (06823.HK)ESG Report of the Year – Middle Market CapitalisationKerry Properties Limited (00683.HK)ESG Report of the Year– Small Market CapitalisationYuexiu Services Group Limited (06626.HK)Outstanding ESG Performance of H-Share CompaniesChina Tower Corporation Limited (00788.HK)Shanghai Electric Group Company Limited (02727.HK)ZTE Corporation (00763.HK)Theme AwardsLenovo Group Limited (00992.HK)Yuexiu Property Company Limited (00123.HK)ZTE Corporation (00763.HK)Photo CaptionsBDO representatives and panel of judges attend the BDO ESG Awards 2024Presentation Ceremony.Representatives of the award winners, BDO, and panel of judges pose for agroup photo at the BDO ESG Awards 2024 Presentation Ceremony. Note to editorsAbout BDO Limited BDO's global organisation extends across 166 countries and territories, with more than 115,600 professionals working in over 1,770 offices - and they're all working towards one goal: to provide our clients with exceptional service. BDO was established in Hong Kong in 1981 and is committed to facilitating the growth of businesses by advising the people behind them. BDO Hong Kong provides an extensive range of professional services including assurance services, risk advisory services, specialist advisory services and tax services. For more details, visit www.bdo.com.hk.ContactsSala LoSenior Marketing Manager and Team HeadBDO Hong KongHeidi LauSenior Marketing ManagerBDO Hong Kong Strategic Financial Relations LimitedVicky LeeYoko LiTel +852 2218 3042Mobile +852 9613 5175salalo@bdo.com.hkTel +852 2218 2325Mobile +852 9285 4151heidilau@bdo.com.hkTel +852 2864 4834sprg_bdo@sprg.com.hkTel +852 2864 4813sprg_bdo@sprg.com.hk Copyright 2024 ACN Newswire via SeaPRwire.com.
GMG’s THERMAL-XR(R) Demonstrates Potential for Electronics Heat Sink Miniaturization and Efficiency
Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - December 11, 2024) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to provide a business update on the commercialisation progress of THERMAL-XR® Powered by GMG Graphene.CUSTOMER ENGAGEMENT UPDATEGMG continues to make progress in testing with companies in multiple industries for the use of THERMAL-XR® in their products, including on heat sinks for electronics. Figure 1 shows an aluminium heat sink that is commonly used in electronics for removing heat from printed circuit boards, electrical circuits and processing silicon chips, and that has been coated with THERMAL-XR®.Figure 1: THERMAL-XR® Coated Electronics Heat SinkTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/233324_9491c90934ed3928_001full.jpgHEAT SINK MINIATURISATION:Third-party verified modelling demonstrates that applying THERMAL-XR® to a heat sink could reduce its size by up to 39%, while maintaining equivalent thermal performance, offering the potential for weight and material cost savings. Figure 2 shows that the maximum temperature reached by a heat sink coated with THERMAL-XR® is 62 degrees centigrade, 23% lower than the maximum temperature of 80 degrees Celsius reached by a heat sink of equal size that has not been coated with THERMAL-XR®. Figure 3 shows that a heat sink coated with THERMAL-XR® that is 39% smaller in terms of width achieves the same performance as a heat sink that has not been coated with THERMAL-XR®.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/233324_9491c90934ed3928_002full.jpgMaterialAmbient Temp. (˚C)Power (W)EmissivityConvection Type Heat Sink Dimensions (mm)Max Temp. (˚C)Temperature Difference Between Aluminium and THERMAL-XR®WidthLengthHeightΔT(˚C)ΔT%Aluminium25800.11Natural Convection62583880-1823%THERMAL-XR®0.9562 Figure 2: Modelling of an Electronic Heat Sink with THERMAL-XR® coated on all sides, excluding the base, shows a 23% reduction in maximum temperature reached.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/233324_9491c90934ed3928_003full.jpgMaterialAmbient Temp. (˚C)Power (W)EmissivityConvection Type No. of FinsHeat Sink Size (mm)Temperature (˚C)WidthLengthHeightΔW%MaxMinAluminium25800.11Natural Convection8625838-8076.7THERMAL-XR®0.955385838-39%8075 Figure 3: A heat sink coated with THERMAL-XR® on all sides, excluding the base, that is 39% smaller achieves the same results and temperature as the bare aluminium heat sink depicted in Figure 1.Global Printed Circuit Board (PCB) production is projected[1] to reach 530 million square meters annually by the year 2030, or about 5.3 trillion printed circuit boards. As PCB density increases, higher current loads lead to more heat, with 5.2 billion units expected to require heat sinks for cooling. THERMAL-XR® coated on the heat sinks, enhances the heat sink efficiency, enabling smaller heat sinks and more compact PCB assemblies. The total amount of THERMAL-XR® that could be used for this application to improve performance is 26.5 million litres per annum by 2030, assuming 0.1% will use the coating.GMG's Managing Director and CEO, Craig Nicol, commented: "Heat sinks are a critical component of modern electronics, but they come with various challenges, especially as devices become smaller, faster, and more powerful. GMG's THERMAL-XR® offers a potential solution in heat sink miniaturization, enabling up to 39% size reduction while maintaining thermal performance. This has the potential to not only cut material costs but also unlock new opportunities for compact and efficient electronics designs, addressing the rising thermal management demands of the global printed circuit board market."About THERMAL-XR® powered by GMG Graphene:THERMAL-XR® COATING SYSTEM is a unique method of improving the thermal heat transfer of heat exchange surfaces. The process coats and protects heat exchange surfaces while increasing the heat transfer rate by leveraging the physics of GMG Graphene, resulting in an efficiency improvement and a potential power reduction.THERMAL-XR® is powered by GMG Graphene. PATENT PENDINGAbout GMG www.graphenemg.comGMG is a clean-technology company which seeks to offer energy saving and energy storage solutions, enabled by graphene, including that manufactured in-house via a proprietary production process. GMG has developed a proprietary production process to decompose natural gas (i.e. methane) into its elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating), lubricants and fluids.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries").GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking Statements This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, the progression of testing and sales of THERMAL-XR® in multiple industries, the benefits of using THERMAL-XR® on heat sinks, the projected growth of PCB production, and the number of PCBs which will require heat sinks in the future.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, that the Company will continue to receive interest in testing and buying THERMAL-XR® from multiple industries, that the use of THERMAL-XR® on heat sinks will result in the benefits expected by management, that the use of THERMAL-XR® will allow heat sinks to be smaller while delivering equivalent thermal performance, that PCB production will grow as currently projected, and that the number of PCBs requiring heat sinks in the future will align with current estimates. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that the Company will not continue to receive interest in testing and purchasing THERMAL-XR® from multiple industries, that THERMAL-XR® will not have the expected benefits when applied to heat sinks, that the size of heat sinks will not be reduced, that PCB production will not grow as expected, that PCBs will not require heat sinks in the future, that THERMAL-XR® coated heat sinks will not enable more compact printed circuit board assemblies, that there will not be demand for THERMAL-XR® in the heat sink market, risks relating to the extent and duration of the conflict in Eastern Europe and its impact on global markets, the volatility of global capital markets, political instability, the failure of the Company to obtain regulatory approvals, attract and retain skilled personnel, unexpected development and production challenges, unanticipated costs and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated October 3, 2024 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.[1] Areas of PCB production projected from the source, Prismark Printed Circuit Board Market Report 2021, page 13To view the source version of this press release, please visit https://www.newsfilecorp.com/release/233324 Copyright 2024 ACN Newswire via SeaPRwire.com.
雲頂新耀:加速腎病領域創新 邁向全球生物製藥領先地位
香港, 2024年12月11日 - (亞太商訊 via SeaPRwire.com) - 據《南華早報》報導,雲頂新耀(HKEX 1952.HK)正加速實現其成為亞太地區領先生物製藥企業的願景。公司憑藉強大的研發實力與卓越的商業化能力,在持續推動業務發展的同時,不斷深化在全球生物製藥領域的佈局。近期,雲頂新耀在核心商業化產品和突破性研究方面取得了一系列重要的里程碑式進展,充分體現了其在為亞洲乃至全球患者提供創新治療解決方案方面的堅定承諾與卓越能力。這些成就不僅鞏固了公司在行業中的領先地位,也進一步彰顯了其致力於滿足未被滿足醫療需求的長期戰略願景。EVER001:腎病創新領域的突破2024年12月4日,雲頂新耀宣佈其自主研發且擁有全球權益的新一代共價可逆布魯頓酪氨酸激酶(BTK)抑制劑EVER001,在1b/2a期臨床試驗階段性資料中取得積極結果。本次試驗聚焦原發性膜性腎病(pMN),是成人原發性腎病綜合征的主要原因,存在未被滿足的醫療需求。近年來,中國pMN的發病率持續上升,成為繼IgA腎病(IgAN)後的第二大腎病綜合征常見的病理類型。目前,中國約200萬原發性膜性腎病患者,而在美國約有8萬-10萬患者,歐洲約8萬患者,日本約4萬患者,疾病負擔在全球範圍內日益加重,且目前全球沒有獲批此適應症的藥物。不同于傳統的共價不可逆BTK抑制劑,EVER001採用獨特的共價可逆機制,結合其強大的靶點結合力與良好的安全性特徵,避免持續抑制帶來的毒副作用。試驗結果顯示,抗-PLA2R自身抗體水準在資料截止日期時已達到接近100%的下降,而早在低劑量組的24周和高劑量組的12周,抗-PLA2R自身抗體下降已超過90%。此外,在已完成36周治療的低劑量組患者中,81.8%的患者實現臨床緩解,高劑量組中已完成24周治療的患者已有85.7%實現臨床緩解。除低劑量組的1例患者外,其他所有完成36周治療的低劑量組患者,以及所有經24周治療的高劑量組患者分別在36周和24周都實現了免疫學完全緩解。EVER001作為一款潛在的同類最佳產品,該結果不僅顯示了EVER001在pMN治療中的高選擇性、優異的藥代動力學特徵、良好的安全性特徵以及強大的靶點結合力,還凸顯了其在其他自身免疫性腎病,如狼瘡性腎炎(LN)、IgA腎病、微小病變病(MCD)和局部節段性腎小球硬化(FSGS)中的廣闊適應症前景。憑藉廣泛的適應症前景、日益增加的疾病發病率以及全球範圍內的開發權益,EVER001成為具有顯著商業價值的「藍海」資產。近年來,腎病治療領域已成為醫藥創新與資本投資的熱點,吸引了眾多跨國製藥巨頭的目光。以2023年為例,Vertex Pharmaceuticals斥資49億美元收購了Alpine Immune Sciences,以獲取其針對腎臟自身免疫性疾病的先進療法。同年,諾華(Novartis)以35億美元收購了Chinook Therapeutics,從而獲得兩項處於後期開發階段的罕見腎病治療藥物。這些交易不僅凸顯了全球醫藥行業對腎病領域的重視,也進一步驗證了該領域創新治療方案的巨大潛力和市場價值。「雙輪驅動」戰略推動商業化成功雲頂新耀通過核心產品耐賦康(R)進一步鞏固了其在腎病治療領域的領導地位。耐賦康(R)是全球首個獲得FDA批准的IgA腎病(IgAN)對因治療藥物,同時也是中國首個獲得IgA腎病適應症的對因治療藥物。該藥物已成功納入2024年國家醫保藥品目錄,這一里程碑不僅顯著提升了患者可及性,還將大幅推動市場滲透率,其相關政策將於2025年1月1日正式實施。自2024年5月在中國大陸商業化上市以來,僅一個月耐賦康(R)銷售額即突破人民幣1.673億元。此外,該藥物還在中國澳門、中國香港、中國台灣、韓國及新加坡獲批,進一步彰顯了雲頂新耀在全球腎病領域的專業實力與市場影響力。雲頂新耀的多元化產品組合還包括氟環素類抗菌藥物依嘉(R)與自身免疫疾病治療藥物伊曲莫德(VELSIPITY(R))。依嘉(R)作為全球首個氟環素類抗菌藥物,在國家衛生健康委抗菌藥物臨床應用與耐藥評價專家委員會發起並主辦的「依拉環素臨床應用綜合評價项目」中表現卓越,臨床療效分析顯示,依拉環素治療3天時的整體有效率為91.1%,治療結束時整體有效率為90.1%。截至2024年上半年,依嘉(R)累計銷售額已達到2.33億元,充分體現了市場對其的高度認可和接受度。在自身免疫疾病領域,伊曲莫德(VELSIPITY(R))的商業化進程取得重要進展。該產品已在中國澳門和新加坡獲批上市,並通過「港澳藥械通」政策率先進入粵港澳大灣區,成為雲頂新耀第三款商業化產品。近期,伊曲莫德的新藥上市許可申請已在中國香港獲正式受理,公司計畫於今年底向中國大陸遞交申請,進一步釋放其市場潛力。在研發領域,經過臨床驗證的mRNA技術平台是公司自主研發的核心部分,公司將自主研發重點轉向擁有全部智慧財產權和全球權益的mRNA腫瘤治療性疫苗。作為公司長期研發戰略的重要支柱,該平臺已實現顯著突破。2024年8月,雲頂新耀啟動一款個性化腫瘤疫苗EVM16的研究者發起的臨床試驗项目(IIT),該研究由北京大學腫瘤醫院和復旦大學附屬腫瘤醫院發起。此外,公司還在積極推進基於mRNA的體內CAR-T專案,用於癌症和自身免疫性疾病的治療,不斷拓展其研發管線的潛在應用。本週一,雲頂新耀股價創下52周新高,盤中最高達49.7港元,收盤47.85港元。自中期業績公佈以來,股價已實現翻倍,充分體現了市場對公司未來發展的強烈信心。通過「雙輪驅動」戰略,雲頂新耀持續聚焦未被滿足的醫療需求,尤其在腎病等關鍵領域表現出色,並以EVER001等突破性療法推動業務增長。憑藉強勁的財務勢頭和清晰的戰略規劃,雲頂新耀正穩步邁向可持續增長,為患者和股東創造長期價值。 Copyright 2024 亞太商訊 via SeaPRwire.com.
Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership
HONG KONG, Dec 11, 2024 - (ACN Newswire via SeaPRwire.com) – As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by robust R&D capabilities and exceptional commercialization expertise.Breakthroughs in Renal Disease Innovation with EVER001On December 4, Everest Medicines announced positive results in preliminary analysis of Phase 1b/2a clinical trial of EVER001, its next-generation, globally owned covalent reversible Bruton’s Tyrosine Kinase (BTK) inhibitor. The trial focuses on primary membranous nephropathy (pMN), a common pathological type of nephrotic syndrome in adults with significant unmet medical needs. The prevalence of pMN in China has been increasing, making it the second most common cause of nephrotic syndrome after IgA nephropathy (IgAN). Currently, there are approximately 2 million patients with pMN in China, 80,000 to 100,000 in the United States, 80,000 in Europe, and 40,000 in Japan,with incidence rates rising in recent years, reflecting its growing global disease burden.Unlike traditional covalent irreversible BTK inhibitors, EVER001 employs a novel covalent reversible mechanism that combines strong target binding with excellent selectivity, significantly reducing off-target toxicity. Positive results in preliminary analysis revealed promising outcomes, with over 90% reductions in anti-PLA2R antibodies and substantial improvements in proteinuria. Additionally, patients in the low-dose cohort who have completed 36 weeks of treatment, 81.8% achieved overall clinical remission, and 91% achieved immunological complete remission. In the high dose cohort, 85.7% patients achieved overall clinical remission and all patients achieved immunological complete remission by week 24. With no currently approved treatments for pMN, EVER001 represents a potentially best-in-class therapeutic candidate. These results highlight EVER001’s potential to deliver best-in-class efficacy and safety, making it a promising treatment not only for pMN but also for a range of other autoimmune glomerular diseases, including lupus nephritis (LN), IgAN, Minimal Change Disease (MCD), and focal segmental glomerulosclerosis (FSGS).With broad indication potential, rising disease prevalence, and Everest Medicines’ global rights, EVER001 represents a high-value asset in a “Blue Ocean” area with significant commercial potential. Kidney disease therapeutics have become a hotspot for innovation and investment in recent years, attracting major multinational pharmaceutical companies. For example, Vertex Pharmaceuticals acquired Alpine Immune Sciences this April for $4.9 billion to access its kidney autoimmune disease therapies. Similarly, Novartis acquired Chinook Therapeutics in June 2023 for $3.5 billion, gaining access to two late-stage treatments for rare, severe chronic kidney diseases.Driving Commercial Success with a Dual-Engine StrategyEverest Medicines continues to strengthen its leadership in nephrology with NEFECON(R), the first FDA-approved treatment for IgAN and the first etiological therapy for IgAN in China. Its inclusion in the 2024 National Reimbursement Drug List (NRDL) marks a significant milestone, enhancing patient accessibility and driving market penetration starting January 1, 2025. Since its commercial launch in May 2024, NEFECON(R) has generated RMB167 million in sales within its first month. The product is also approved in Macau, Hong Kong, Taiwan, South Korea, and Singapore, further cementing Everest’s expertise in nephrology.Everest’s diversified portfolio also includes XERAVA(R) and VELSIPITY(R). XERAVA(R), a novel broad-spectrum antibiotic, demonstrated an overall effectiveness rate of 90.9% after three days of treatment in the "Comprehensive Evaluation Project on the Clinical Application of Eravacycline", contributing RMB134 million in revenue in H1 2024. VELSIPITY(R), approved under the "Hong Kong and Macau Medicine and Equipment Connect" policy, is now available in three designated medical institutions within the Greater Bay Area. It has also received approvals in Macau and Singapore, with an NDA accepted in Hong Kong and plans for an NDA submission in Mainland China by year-end.Everest is accelerating innovation through its proprietary mRNA platform, a cornerstone of its long-term R&D strategy. In August 2024, Everest launched an Investigator-Initiated Clinical Trial for EVM16, a personalized mRNA cancer vaccine, at Peking University Cancer Hospital and Fudan University Cancer Hospital. The company is also advancing mRNA-based in vivo CAR-T programs for cancer and autoimmune diseases, expanding its pipeline’s potential.As of now, Everest Medicines reached a 52-week high of HKD 49.7, closing at HKD 47.85. Since announcing its mid-year results, the stock price has more than doubled, reflecting strong investor confidence. With its dual-engine strategy, Everest has positioned itself as a rising leader in the global biopharmaceutical industry, focusing on unmet medical needs, particularly in renal diseases, and breakthrough therapies like EVER001. Supported by strong financial momentum and a clear vision, Everest is poised for sustainable growth and lasting value for patients and shareholders. Copyright 2024 ACN Newswire via SeaPRwire.com.
Combating customer harassment: Fujitsu, Toyo University and Kokoro Balance Research Institute launch field trial on AI-powered training program
Tokyo and Kawasaki, Japan, Dec 11, 2024 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited, Toyo University Incorporated Educational Institution (Toyo University) and Kokoro Balance Research Institute today announced the commencement of a field trial on December 3, 2024, to develop a Training Program for Coping with Customer Aggression. This program leverages AI and incorporates insights from criminal psychology and mental health to tackle the growing societal issue of customer harassment, i.e., unreasonable or abusive behavior directed at staff by customers and clients.The program utilizes the “AI Tool for Experiencing Customer Aggression” developed using Fujitsu's generative AI technology, behavior change support technologies and Toyo University's expertise in criminal psychology. Fujitsu’s AI tool provides interactive feedback through the use of AI avatars and clarifies actions that can be taken to enhance participants' customer harassment response skills. To evaluate the program's effectiveness, Kokoro Balance Research Institute will leverage its mental health expertise to develop new psychological scales measuring customer service skills, stress management, and overall customer harassment response capabilities. Furthermore, the research partners will carry out a field trial with call center employees at Fujitsu Communication Services Limited (CSL), analyzing changes in participants' customer service skills, stress management, engagement, and subjective productivity to ensure the program's scientific validity.The full program is targeted for launch in fiscal 2025 with the goals of reducing the psychological burden of working people in customer service roles and contributing to the creation of safe and supportive work environments.BackgroundCustomer harassment has become a serious social issue. A recent survey revealed that 46.8% of service industry workers have encountered customer harassment in the past two years, with nearly half experiencing lasting physical and mental health consequences.In response, the Ministry of Health, Labour and Welfare added mental health issues related to customer harassment to its work-related injury recognition criteria in September 2023. Furthermore, the Tokyo Metropolitan Assembly passed Japan's first customer harassment prevention ordinance in October 2024. The growing national and local government efforts are driving increased organizational responsibility for employee protection.Field Trial PeriodDecember 3, 2024 to March 31, 2025Figure 1: Overview diagram of the field trial Comment from Akiko Yamada, Head of the Converging Technologies Laboratory of Fujitsu Research, Fujitsu Limited:We have been pursuing research in converging technologies, combining cutting-edge digital technology with knowledge from humanities and social sciences to solve various social issues. This new initiative combines generative AI, behavioral change support technology, criminal psychology, and mental health expertise to tackle the significant social problem of customer harassment and secure the well-being of working people.Comment from Prof. Masayuki Kiriu, Dean, Faculty of Sociology, Toyo University:By incorporating psychological scales and stress measurement indicators into the "AI Tool for Experiencing Customer Aggression”, we expect to create a practical and effective customer harassment response training program for customer service personnel. This will significantly contribute to solving current customer harassment issues. We anticipate the emergence of new social contributions through converging technology in this pilot program.Comment from Kyoko Shimada, Representative Director, Kokoro Balance Research Institute:Customer harassment can inflict deep emotional wounds on employees. While eradication may be impossible, we can reduce its impact through organizational efforts. This research aims to strengthen organizations by focusing on employee mental health and response capabilities. By using globally recognized psychological scales and effective evaluation criteria, we aim to make this program scientifically sound, useful, and applicable for employees.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press Contacts:Fujitsu LimitedPublic and Investor Relations DivisionInquiriesToyo UniversityToyo University General Affairs Department, Public Relations DivisionPhone: 03-3945-7571Reception hours: 9:00-18:00 JST (excluding Saturdays, Sundays, holidays, and university-designated holidays)E-mail: mlkoho@toyo.jpKokoro Balance Research InstituteE-mail: info@kokorobalance.jp Copyright 2024 JCN Newswire via SeaPRwire.com.
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China
SHENZHEN, CHINA, Dec 9, 2024 – (ACN Newswire) – On 6 December, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) have been issued in China, which marks that the first oral methylthioninium chloride enteric-coated sustained-release tablets in China has officially entered clinical application. The Product is indicated for enhancing visualization of colorectal lesions in adult patients undergoing screening or surveillance colonoscopies. Lumeblue® is an oral diagnostic drug that uses patented multi-matrix (MMXTM) technology to deliver active substances directly to the colon and release them locally in a controlled manner. As an enhancer dye, the Product increases the contrast between colorectal lesions and healthy mucosa. The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas (the secondary endpoint)[1]. In addition, the Product can be taken during the bowel preparation step, ensuring that colorectal staining is completed by the time colonoscopy is conducted. This not only enhances the detection rate of colorectal lesions but also potentially simplifies the colonoscopy procedure, making the examination more efficient and improving the screening benefits. According to the diagnosis and treatment data of the Digestive Endoscopy Branch of the Chinese Medical Association, approximately a total of 28 million gastroenteroscopies were completed nationwide in 2012, including 5.83 million colonoscopies. In 2019, approximately 38.73 million gastroenteroscopies were completed nationwide, an increase of 34.62% compared with 2012[2]. The Expert consensus on the early diagnosis and treatment of colorectal cancer in China (2023 edition) recommends colorectal cancer screening for individuals aged 40 to 74[3]. Based on the China Statistical Yearbook (2023), the total population of this age group in China is 643.36 million[4]. With the popularization of early colorectal cancer screening in China, the number of colonoscopies performed is expected to have significant growth potential in the future. Early diagnosis and removal of lesions are crucial for prevention. Lumeblue® provides an innovative solution for colorectal disease screening and management in response to this growing demand. The Product has been approved by the European Medicines Agency (EMA) to be commercialized in the European Union under the trade name Lumeblue® in August 2020. The Group obtained an exclusive license for the Product from Cosmo Technologies Ltd., a fully-owned subsidiary of Cosmo Pharmaceuticals NV, on 3 December 2020. Following its approval in China in June 2024, CMS worked collaboratively across its business segments to ensure the rapid importation of the first batch of products. The Group has also actively leveraged its existing gastroenterology portfolio and resources to orderly advance the commercialization and academic promotion of Lumeblue®, facilitating its successful prescriptions launch in China. With this milestone, CMS’s five innovative drugs have been successfully approved in China and fully entered clinical application. This achievement demonstrates the Group’s ongoing capability of innovation transformation, while reflecting CMS’s commitment to focusing on medical value and fulfilling its corporate social responsibility. Looking ahead, CMS will continue to be patients-centered, efficiently advancing the clinical development and commercialization of innovative products. The Group is dedicated to improving the accessibility and affordability of innovative drugs, benefiting a broader patient population. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group. References: 1. The results of the Product’s Phase III clinical trial in China were published and are available at: https://web.cms.net.cn/en/2022/12/positive-results-for-china-phase-iii-clinical-trial-of-methylthioninium-chloride-enteric-coated-sustained-release-tablets/ 2. Data from the Digestive Endoscopy Branch of the Chinese Medical Association 3. Early Diagnosis and Treatment Group of the Chinese Society of Oncology. “Expert Consensus on Early Diagnosis and Treatment of Colorectal Cancer in China (2023 Edition).” Chinese Medical Journal, 2023, 103(48): 3896-3908. DOI: 10.3760/cma.j.cn112137-20230804-00164 4. National Bureau of Statistics. (2023). China Statistical Yearbook 2023. Retrieved from https://www.stats.gov.cn/sj/ndsj/2023/indexch.htm CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
FxPro Group Announces the Launch of BankPro: A Private Digital Banking Solution
Nassau, the Bahamas – December 11, 2024 – (SeaPRwire) – FxPro Group, a global leader in financial services and trading, has launched BankPro, a cutting-edge Private Digital Bank designed to redefine digital financial solutions for individuals and corporations. BankPro combines private banking services with advanced investment and trading capabilities, offering clients a seamless, all-in-one application tailored to their financial needs. The launch of BankPro underscores FxPro Group’s commitment to innovation and excellence, leveraging its 25 years of expertise and $120 million in Tier 1 company capital to introduce a next-generation digital banking solution. BankPro is regulated by the Central Bank of The Bahamas and operates with the highest standards of security and compliance. Key Features of BankPro: Multi-Currency Accounts BankPro provides access to over 24 currencies, enabling effortless international transactions at competitive exchange rates. Clients can manage their finances globally with a single account designed for both personal and corporate use. Visa Platinum Cards Clients can access exclusive Visa Platinum cards, offering customizable spending limits, global acceptance, and enhanced security. Additionally, instant virtual cards provide a secure and efficient solution for online transactions, making BankPro a versatile option for all financial activities. Global Banking with Flat Fees BankPro simplifies international banking with flat-fee structures, ensuring transparent and predictable costs. This approach is particularly advantageous for high-value transactions, providing clarity and value for clients engaged in global business and personal finance. Comprehensive Investment and Trading Platform BankPro integrates investment and trading capabilities, allowing clients to manage and grow their portfolios within the same platform. Key features include: Investing in over 2,100 Stocks and ETFs: Clients gain access to major exchanges, including NYSE, Nasdaq, LSE, XETRA, and Euronext. Real-Time Market Data: Active subscriptions include free live pricing from Nasdaq and LSE. Through FxPro Global Markets Ltd., clients can also trade over 200 Derivatives across Forex, Commodities, Metals, Indices, Stocks, and ETFs, enabling portfolio diversification and risk management. Corporate Banking Solutions BankPro offers tailored services for businesses, including multi-currency accounts, streamlined expense management tools, and advanced treasury management solutions. Corporate clients benefit from high-spending Visa Platinum cards, detailed reporting tools, and access to flexible investment options. A Strong Foundation in the Bahamas BankPro operates from its state-of-the-art headquarters in Lyford Cay, Nassau. The facility reflects the company’s commitment to The Bahamas as a central hub for its operations. The company also has an office in the City of London, UK. As a fully regulated entity, BankPro prioritizes security and reliability, holding a professional membership with the Association of International Banks and Trust Companies. The company’s regulatory foundation ensures robust protection for clients, complemented by advanced digital onboarding tools and fraud prevention measures. These features, combined with the FxPro Group’s legacy of excellence, make BankPro a trusted partner for financial services. About FxPro Group With 25 years of experience, the FxPro Group is a global leader in financial services, offering trading solutions across Forex, Commodities, and more. With a presence in over 170 countries and $200+ million invested in elite sponsorships, FxPro has earned over 120 industry awards for its innovative technology and reliable services. The launch of BankPro marks the Group’s expansion into digital private banking, combining its expertise in trading with cutting-edge financial solutions designed for the modern client. To know more please contact +1 242 603 2226. Media Contact Brand: BankPro Limited Contact: Media team Email: info@bankpro.com Website: https://www.bankpro.com The article is provided by a third-party content provider. SeaPRwire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Sectors: Top Story, Corporate News SeaPRwire provides real time press release distribution for companies and organizations to 6,500+ media outlets & 3.5 million professional desktops in 90 regions. It distributes press releases in different languages, including: IndonesiaFolk, IndoNewswire, SEATribune, IDNewsZone, LiveBerita, DailyBerita, TaiwanPR, SinchewBusiness, AsiaEase, BuzzHongKong, SingapuraNow, TIHongKong, TaipeiCool, TWZip, AsiaFeatured, dePresseNow, THNewson, KULPR, VNFeatured, MENAEntry, HunaTimes, DubaiLite, ArabicDir, BeritaDaring, TekanAsia, JamKopi ...
順豐控股進軍港股 書寫國際化發展新篇章
香港, 2024年12月10日 - (亞太商訊 via SeaPRwire.com) - 據經濟日報報道,隨著全球企業供應鏈的重塑、中國企業出海以及跨境電商的推動,市場對更高效、更靈活、更綜合的物流服務的需求不斷攀升。順豐控股股份有限公司(「順豐控股」,股份代號:6936.HK)以其獨特的業務模式和強大的網絡優勢,積極佈局國際物流服務,投身於時代革新發展的浪潮中。根據弗若斯特沙利文,按2023年收入計,順豐控股是中國及亞洲最大的綜合物流服務提供商,也是全球第四大綜合物流服務提供商,僅次於聯合包裹服務公司(UPS)、敦豪(DHL)和聯邦快遞(FedEx)。公開資料顯示,順豐控股連續多年位居《財富》世界500強企業之列。2024年,公司獲評《財富》最受讚賞的中國公司第二位,且連續8年上榜「《財富》最受讚賞的中國公司」。11月27日,順豐控股登陸港交所,掀開國際化發展新篇章。夯實物流基礎網絡 持續迎來盈利兌現順豐控股最早於2010年即開始運營國際業務,主要服務中國客戶的出境物流需求。如今,隨著中國企業出海,國際供應鏈蘊含著重大轉型機遇。2021年,公司攜手嘉里物流,進一步強化了在東南亞的本土及跨境快遞、國際供應鏈和國際貨代能力。通過與嘉里物流的融通,其國際綜合物流能力和客戶基礎得到進一步強化,為實現國際拓展的戰略和願景提供了重要助力。根據弗若斯特沙利文報告,按國際收入計,2023年順豐的國際業務規模已在所有亞洲綜合物流服務提供商中排名第一。值得關注的是,經過多年投入後,順豐控股已度過資本開支的高峰期,迎來更高質量增長週期。一方面,業務規模擴張持續攤薄基礎設施邊際成本,提升其營業利潤率。另一方面,公司新業務陸續進入"收獲期",提供公司盈利彈性。具體而言,經濟產品體系升級,助力利潤穩步增長;大件業務於2022年淨利潤轉盈,2023年在降本提效作用下盈利能力持續增厚;同城業務於2023年首次實現全年盈利,2024年延續高增長。得益於此,順豐控股盈利能力持續增強,2024年前三季度,其收入同比增加9.4%,淨利潤同比增加28.0%。淨利率達到3.7%,同比提升了0.5個百分點。未來,在上述因素的共同推動下,公司盈利能力有望進一步增強。加速推進國際業務 打開中長期成長空間對於順豐控股而言,從亞洲到全球,是其發展的必然。為此,公司積極參與建設鄂州貨運樞紐,作為亞洲第一、全球第四座以貨運為主的物流樞紐,鄂州貨運樞紐的投產將進一步擴大公司與同業在配送時效以及網絡方面的差異化優勢,促進公司降本增效,為國際業務拓展奠定了堅實的基礎。隨著位於鄂州貨運樞紐的分揀及轉運中心投入運營,憑藉豐富的產品組合、綜合的全球能力、併購經驗、卓越的運營及精益的成本管控,順豐控股能夠有效整合市場並把握國內外的市場機遇。順豐控股高管曾表示,赴港上市是出於國際化的長遠考慮,最主要目的是利用全球化資本,實現規模快速擴張。本次上市,順豐控股計劃將募集資金的45%用於加強其國際及跨境物流能力,此將進一步提升公司國際產品的廣度及深度,助力公司國際業務加速拓展。同時,H股上市也有助於提升公司品牌影响力及市場竞争力。在豐富的物流網絡、領先的成本優勢和綜合物流能力的支撐下,順豐控股有望搶佔更大的全球市場份額,推動公司投資價值的不斷增長。 Copyright 2024 亞太商訊 via SeaPRwire.com.
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections
KNOXVILLE, Tenn., Dec 10, 2024 - (ACN Newswire via SeaPRwire.com) - VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites.RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular therapy that may be safe, effective, and cost-efficient. The treatment has shown rapid infection resolution and improved patient outcomes in clinical trials across the U.S., India, Brazil, and Mexico."RB PDAT is a revolutionary, non-invasive treatment showing remarkable promise for patients with severe infectious keratitis. This innovative therapy harnesses the power of light to combat infection and offers new hope for preserving vision," said Jean-Marie Parel, IngETS-G, Ph.D., FAIMBE, FARVO, Director and co-founder of the Ophthalmic Biophysics Center at BPEI.Guillermo Amescua, M.D., Professor of Clinical Ophthalmology, Medical Director of the Ocular Microbiology Laboratory, and a board-certified ophthalmologist at BPEI added, "VisiRose is crucial for translating the innovation of RB PDAT from the laboratory to a widely accessible treatment, ultimately benefiting countless patients worldwide.""VisiRose is the bridge that connects innovation with impact. It enables us to bring the hope of RB PDAT to patients who desperately need it, transforming lives and shaping the future of eye care," said Ed Pershing, Chairman of the Board of Directors of VisiRose and Provectus.Dominic Rodrigues, Acting CEO of VisiRose added, "RB PDAT offers a beacon of hope for patients facing the threat of vision loss from infectious keratitis. This innovative therapy, with its targeted action and dual benefits, represents a significant advancement in eye care, paving the way for a brighter future for those struggling with this challenging condition."In more than 500 patients, RB PDAT has shown promising results in treating severe eye infections where traditional therapies have failed. VisiRose is poised to address a significant gap in the $60 billion global ophthalmic market, focusing on regions and populations impacted by rising AMR and the lack of access to effective treatments.About VisiRoseVisiRose is a newly launched, clinical-stage biotechnology company of the University of Miami and Provectus Biopharmaceuticals, focused on commercializing the Miller School of Medicine's Bascom Palmer Eye Institute and its Ophthalmic Biophysics Center's innovative ocular research using Provectus's bioactive synthetic small molecule Rose Bengal Sodium (RBS). For more information, please visit: https://visirose.com.About Bascom Palmer Eye InstituteThe Bascom Palmer Eye Institute, part of the University of Miami Health System, is consistently ranked #1 in ophthalmology in the U.S. by U.S. News & World Report. Known for its cutting-edge research and clinical excellence, Bascom Palmer provides world-class care across all ophthalmic subspecialties and is at the forefront of developing innovative treatments for eye diseases. With a commitment to advancing both patient care and medical research, it is recognized globally as a leader in ophthalmology. For more information, please visit: https://umiamihealth.org/en/bascom-palmer-eye-institute.About Provectus BiopharmaceuticalsProvectus Biopharmaceuticals (OTCQB: PVCT) is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of bioactive synthetic small molecules called halogenated xanthenes. The Company's lead molecule is named Rose Bengal Sodium. Provectus's drug platform includes:Clinical development programs in oncology, dermatology, and ophthalmology,In vivo proof-of-concept programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers, andIn vitro discovery programs in infectious diseases, tissue regeneration and repair, and several proprietary targets.Information about the Company's clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For more information, please visit: www.provectusbio.com.For Media Inquiries:VisiRose, Inc.E: contact@visirose.comW: visirose.comContact:VisiRose, Inc.Dominic RodriguesActing Chief Executive OfficerE: rodrigues@visirose.comSOURCE: VisiRose Copyright 2024 ACN Newswire via SeaPRwire.com.
Provision of the First Template Function Adapted to the IFRS Sustainability Disclosure Standards in Japan (IFRS S1 and S2) on the Sustainable Finance Platform
TOKYO, Dec 10, 2024 - (JCN Newswire via SeaPRwire.com) - The Association for Promotion of Sustainable Finance Platform (AP-SFPF) and Hitachi, Ltd. (Hitachi) today announced that we will begin providing the first template feature adapted to the IFRS sustainability disclosure standards in Japan (IFRS S1 and S2*1) formulated by the International Sustainability Standards Board (ISSB), on the Sustainable Finance Platform - Engagement Support Service (SFP-ESS), a digital platform that promotes ESG investing by establishing seamless connections between asset management companies and listed companies.Specifically, Hitachi's SFP-ESS, developed under license from the IFRS Foundation, will be enhanced with a templatedesigned to facilitate reporting in accordance with IFRS S1 and S2 and the SASB Standards*2 (Templates). AP-SFPF will offer the Templates to asset management companies and listed companies in Japan as the service provider.By starting to provide the Templates, AP-SFPF and Hitachi will support listed companies in Japan in their disclosure of information in conformance with IFRS S1 and S2 and communication between listed companies and assetmanagement companies. This will enable global institutional investors to properly evaluate sustainability-conscious corporate activities in the ESG perspective and contribute to the enhancement of the companies' corporate value.AP-SFPF is a general incorporated association that was established to connect diverse stakeholders andpromote effective and efficient communication, solving issues and considering projects to contribute to the continued development of the ESG market. It was established in July 2023 by eight companies, which mainly include financial institutions: MS&AD Insurance Group Holdings, Inc., Sompo Japan Insurance Inc., Tokio Marine & Nichido Fire Insurance Co., Ltd., Nippon Life Insurance Company, Hitachi, Ltd., Mizuho Bank, Ltd., Sumitomo Mitsui Banking Corporation, and MUFG Bank, Ltd.Background of the start to adapt the SFP-ESS for IFRS S1 and S2Recently, investors' interest in companies' sustainability initiatives has been growing and companies are implementing sustainability initiatives and disclosing information about them. However, there are various disclosure standards in Japan and global. This has created an issue regarding disclosures. The people in charge of disclosing information,especially people at listed companies engaging in business globally, are not sure which standards to refer to and unable to determine investors' expectations regarding the disclosure of information, in addition to being short of resources. To solve this situation, the ISSB announced IFRS S1 and S2 in June 2023 as global baseline standards forthe disclosure of sustainability-related information.In Japan, the Sustainability Standards Board of Japan (SSBJ) is formulating the Japanese version of S1 and S2 (the SSBJ standards), which are made to comply with all of the requirements of IFRS S1 and S2, the standards fordisclosing sustainability-related informationin Japan. The finalized standards are planned to be published by March 2025. In addition, the Financial ServicesAgency made it mandatory to disclose sustainability-related information in securities reports in the fiscal year ended March 31, 2023. It is also considering the gradual application of the SSBJ standards to companies listed on the PrimeMarket starting in the fiscal year ending March 31, 2027. Therefore, listed companies are facing urgent tasks, such asthe collection of sustainability-related information and the development of a disclosure process in line with IFRS S1and S2, to prepare for the disclosure of information becoming mandatory in the future and to enhance their corporate value.In response, AP-SFPF exchanged opinions with more than 100 companies, including asset management companiesand listed companies, and began to offer a beta version of the SFP- ESS and verify its value in October 2023 to reduce the workload of the people at listed companies in charge of disclosing information and promote ESG investingin Japan. By using the Templates to adapt the SFP-ESS to IFRS S1 and S2, AP-SFPF and Hitachi will help listed companies smoothly disclose ESG information and contribute to improving their corporate value.Outline of SFP-ESSThe SFP-ESS is a two-sided platform on which asset management companies and listed companies making ESG investments are connected seamlessly to deepen their mutual understanding of each other. Asset managementcompanies present their needs regarding the ESG information it expected that listed companies disclose in line with theSASB*2 Standards. Listed companies refer to this registered information, which enables them to understand the needs of asset management companies and use the information when formulating their disclosure policies.Listed companies enter their data into the platform and send it, publishing it alongside comments by following the disclosure items in the Templates. This facilitates asset management companies' side-by-side comparison of listedcompanies as the viewers and also enables them to understand data, including the details.Features of the Templates adapted to IFRS S1 and S2Regarding IFRS S1 and S2, documents explaining the disclosure standards themselves, the IFRS Sustainability Disclosure Taxonomy*3, and support materials including a guide for the voluntary application of ISSB Standards havebeen published. However, Japanese documents are limited, and each company is left to decide how they will disclose the information they should disclose in their integrated reports and other reports. To support the practical tasks done by these listed companies, the Templates come with an input interface available in Japanese, so that digital data can be entered and saved on the platform in accordance with definitions in the taxonomy. Specifically, the Templates helplisted companies understand and respond to IFRS S1 and S2 using the following three features.1. Disclosure items classified into three categories (major categories, intermediate categories, and subcategories)The IFRS Sustainability Disclosure Taxonomy information is classified in detail into four core classifications (governance, strategy, risk management, and metrics and targets). However, the hierarchical structure differs from item to item. In response, a creative measure was devised to streamline data entry by the people in charge ofthe disclosure of information at listed companies by classifying the information into major categories,intermediate categories and subcategories visualizing the hierarchical structure of the information. This helps the people in charge of disclosing information at companies understand information collection based on the definitions in IFRS S1 and S2 without difficulty.2. Supplementary information from the IFRS Foundation regarding each disclosure item is provided when viewing the Templates.The IFRS Foundation, provides application guidance which companies may want to refer to when entering information into the Templates.3. Tables styles and options enabling an intuitive understanding of the information that needs to be disclosed are availableOptimal table styles are provided on an item-by-item basis to enable people to intuitively understand and enter the information required for each disclosure item. For example, there is an appropriate answer space for itemsthat are yes or no questions. In addition, for items which require that risks be described, there is a multiple-choice section about the type of risk (physical or transition) and the time frame (short, medium, or long term), in addition to the space for describing the risk. This prevent the omission of information or the provision of insufficient information.Future developmentMoving forward, AP-SFPF and Hitachi will broadly expand the SFP-ESS with the Templates to listed companies andtalk with multiple listed companies preparing to comply with IFRS S1 and S2 ahead of others. It will thus collect opinionsand requests regarding the improvement of the convenience of the Templates and develop the Templates so that we are more useful and adapted to IFRS S1 and S2.We will also work to functionally enhance the SFP-ESS in addition to developing the Templates. Specifically, they moveforward with consideration and development to provide service features which will be needed in the promotion ofthe disclosure of information, dialogue, and engagement between asset management companies and listedcompanies, such as a feature enabling asset management companies to register their information disclosure needs, and to release these features one by one. We also plan to incorporate the finalized SSBJ standards which will be published by the SSBJ by March 2025.Speaking at Director of Earned Revenue, IFRS Sustainability, Eli Reisman, said:“The IFRS Foundation welcomes Hitachi as a licensee of its standards. The IFRS Foundation encourages companiesvoluntarily applying IFRS S1 and IFRS S2, in addition to the progress being made towards regulatory adoption or other use of IFRS S1 and IFRS S2 happening in 25+ jurisdictions globally. In order to facilitate this corporate disclosure, it’s imperative that various services and tools integrate the ISSB standards to support this process."Yasuki Imai, Vice President and Executive Officer, Head of Digital Systems & Services APAC Business, and CEO of Financial Institutions Business Unit, Hitachi, Ltd, said:“In line with this approach to sustainability reporting, Hitachi and its only reseller of SFP-ESS, The Association forPromotion of Sustainable Finance Platform, aim to facilitate the application of IFRS S1, S2, and SASB standards and provide guidance on industry-specific disclosures through the SFP-ESS platform: SFP-ESS is a digital platformdesigned to support companies in their sustainability reporting efforts. This tool is intended to assist companies in navigating the reporting process, with the goal of enhancing the standardization and relevance of ESG reporting.”AP-SFPF member company, Managing Executive Officer, Group Chief Sustainability Officer (CSuO), MS&AD Insurance Group Holdings, Inc., Naomi Motojima said:“MS&AD Insurance Group Holdings, Inc. engages in investment, lending and insurance underwriting activities in consideration with ESG as a signatory to Principles for Sustainable Insurance (PSI) and the Principles for ResponsibleInvestment (PRI). We consider “Symbiosis with global environment ~Planetary Health~” as an important issue forMS&AD group, and we are working on realizing “Action on climate change” and “Improvement of sustainability of natural capital” comprehensively to enhance the resilience of society. We help to solve ESG issues including climate change through insurance underwriting, investment and lending, and of course we also work to reduce our own Greenhouse gas (GHG) emissions. We regard them as missions that we have as an insurance and financing serviceprovider. SFP-ESS is a platform that increases the mutual understanding of companies and financial institutions regarding ESG information disclosure. We hope that using the disclosure templates adapted to S1 and S2, which will be newly implemented, will facilitate the disclosure of information related to companies' ESG activities and lead to investors appropriately evaluating the companies. Further, from the standpoint of an investor, we find the developmentof a platform which enables users to compare the information disclosed by companies using a same index beneficial in the activities for the appropriate evaluation of the activities of the companies. Therefore, we welcome the release of the template feature.”*1 Disclosure standards announced by the IFRS Foundation in June 2023. The standards consist of IFRS S1 (General Requirements for Disclosure of Sustainability-related Financial Information) and IFRS S2 (Climate-related Disclosures).*2 The Sustainability Accounting Standards Board (SASB) Standards provide industry-specific ESG disclosure guidance focused on financial materiality. As of August 2022, the International Sustainability Standards Board (ISSB) of the IFRS Foundation assumed responsibility for the SASB Standards.*3 The IFRS Sustainability Disclosure Taxonomy is a framework for digitally tagging sustainability-related financial disclosures Its goal is to digitalize informationand facilitate investors' and stakeholders' comparison and assessment of companies' sustainability performanceSFP-ESS websitehttps://sfp-ess.org/en/service/About the Association for Promotion of Sustainable Finance Platform (AP-SFPF)The AP-SFPF was established in July 2023 to solve issues and consider projects, with financial institutions playing a leading role, to create new value and contribute to the continued development of the ESG market, eventually resultingin the sustainable development of society through the connection of various stakeholders to each other and the provision of a platform which will facilitate efficient and effective communication related to ESG issues.Member companies: MS&AD Insurance Group Holdings, Inc., Sompo Japan Insurance Inc., Tokio Marine & NichidoFire Insurance Co., Ltd., Nippon Life Insurance Company., Hitachi, Ltd., Mizuho Bank, Ltd., Sumitomo Mitsui Banking Corporation., MUFG Bank, Ltd.Representative: Yoshihiro Kanaoka, Representative Director Location: 1-6-1 Marunouchi,Chiyoda-ku, Tokyo 100-8220, Japan Corporate website: https://sfp-ess.org/en/About Hitachi, Ltd.Hitachi drives Social Innovation Business, creating a sustainable society through the use of data and technology. We solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products. Hitachi operates under the 3 business sectors of “Digital Systems & Services” – supporting our customers’ digital transformation; “Green Energy & Mobility” – contributing to a decarbonized society through energy and railway systems, and “Connective Industries” – connecting products through digital technology to provide solutions in various industries. Driven by Digital, Green, and Innovation, we aim for growth through co-creation with our customers. The company’s revenues as 3 sectors for fiscal year 2023 (ended March 31, 2024) totaled 8,564.3 billion yen, with 573 consolidated subsidiaries and approximately 270,000 employees worldwide. For more information on Hitachi, please visit the company's website at www.hitachi.com. Copyright 2024 JCN Newswire via SeaPRwire.com.
Fujitsu drives business process improvement at Mitsubishi Electric Engineering using SAP Signavio(R)
Fujitsu today announced that it has provided Mitsubishi Electric Engineering with process visualization and analysis services utilizing the process mining(1) capabilities of “SAP Signavio®”(2), a platform that supportsbusiness transformation. Fujitsu consultants also identified areas requiring improvement and offered recommendations for process optimization.Mitsubishi Electric Engineering implemented its current system using SAP S/4HANA® in 2022 and planned a system upgrade for 2025. To optimize costs and efficiency before the upgrade, the company evaluated the effectiveness of its key business processes, such as sales and procurement, focusing on areas for improvement in operational quality and process standardization.To support this evaluation, Fujitsu employed its visualization and analysis service, which continuously monitors, analyses, and evaluates the effects of the current system's implementation. By visualizing the entire business process using log data from the current system, Fujitsu identified bottlenecks and process inconsistencies. Fujitsu consultants, with their deep understanding of SAP solutions, then used this information to propose process improvements.These improvement proposals were then discussed and refined in workshops with Mitsubishi Electric Engineering, leading to a clear identification of business challenges and improvement strategies. This data-driven approach, compared to traditional consulting methods relying solely on client interviews, enabled a rapid clarification of the current situation. This shortened the usual six to twelve-month evaluation phase to approximately one month, allowing more time for in-depth discussions on core business issues.Fujitsu will continue to support Mitsubishi Electric Engineering's process improvement initiatives. Through this collaboration, Fujitsu aims to help various companies achieve continuous process improvement and enhance their ability to adapt to changing business environments.(1) Process mining: Analytical method for discovering, monitoring, and improving actual processes based on easily accessible event logs from existing information systems.(2) SAP Signavio®: Platform provided by SAP SE (Germany) that supports business process management.Fujitsu’s Commitment to the Sustainable Development Goals (SDGs)The Sustainable Development Goals (SDGs) adopted by the United Nations in 2015 represent a set of common goals to be achieved worldwide by 2030.Fujitsu’s purpose — “to make the world more sustainable by building trust in society through innovation” — is a promise to contribute to the vision of a better future empowered by the SDGs.About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers in over 100 countries, our 124,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: Computing, Networks, AI, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.7 trillion yen (US$26 billion) for the fiscal year ended March 31, 2024 and remains the top digital services company in Japan by market share. Find out more: www.fujitsu.com.Press ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2024 JCN Newswire via SeaPRwire.com.
巴西總統魯拉緊急腦部手術後入住加護病房
(SeaPRwire) - 聖保羅——巴西總統正在接受腦出血手術後,在加護病房中恢復中,Sirio-Libanes醫院在週二凌晨的一份聲明中表示。 這項手術是在這位79歲的左翼領袖在10月份感到頭痛後進行的,醫生認為頭痛是由於……造成的。 醫院表示,魯拉從首都巴西利亞前往1000公里(620英里)以南的聖保羅接受治療,在出血被引流後,「情況良好,正在加護病房的病床上接受監控」。 巴西總統府尚未發表任何評論。 魯拉的辦公室當時表示,他因意外事故取消了前往俄羅斯參加金磚國家峰會的行程。事故在他頭後部、靠近頸部的地方留下了一道可見的傷口。 Sirio-Libanes表示,將於當地時間上午9點(格林威治標準時間凌晨12點)舉行記者會,討論手術情況。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。














